The greater use of flavoured snus among ever-smokers versus never-smokers in Norway

Harm Reduction Journal - 2020
Tord Finne Vedøy1, Karl Erik Lund1
1Department Alcohol, Tobacco and Drugs, Norwegian Institute of Public Health, PO Box 222, 0213, Skøyen, Oslo, Norway

Tóm tắt

AbstractBackgroundSimilar to the debate around e-cigarettes, an increase in snus use among Norwegian adolescents has prompted debate on whether flavour options in snus should be limited. To this end, we compared use of flavoured snus among snus users with different smoking status.MethodsQuestions about flavoured snus use were included in an online omnibus study conducted from 2015 to 2019 (N = 65,445) that included 16,295 ever snus users (aged 15+). Current snus users (N = 9783) were asked “Do you usually use snus that has a flavouring (liquorice, mint, wintergreen, etc.)? Adjusted predicted probabilities and 95% confidence intervals (CI) were calculated from a logistic regression model.ResultsLess than 25% of the snus users reported never having smoked. The overall probability of using flavoured snus was .45 (95% CI .44–.46), highest among daily (.51, 95% CI .47–.54) and former daily smokers (.50, 95% CI .48–.52), and lowest among never (.41, 95% CI .39–.43) and occasional smokers without any prior history of daily smoking (.41, 95% CI .38–.44). Use of flavoured products was higher among female snus users (p = .67, 95% CI .65–.69) compared to males (p = .35, 95% CI .34–.36), highest among the youngest age group, 15–24 years (p = .58, 95% CI .56–.60) and decreased with increasing age.ConclusionRegulation that would ban or limit flavoured snus use may affect smokers—an at risk population—more than never smokers. The health authorities should be mindful of the real-world complexity governing potential harms and benefits of flavour restrictions on snus. A further assessment of flavour limitations should acknowledge that flavoured snus products also function as alternatives to cigarettes.

Từ khóa


Tài liệu tham khảo

GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2012;390:1345–422.

Scientific Committee on Emerging and Newly-Identified Health Risks (SCENHIR). Health Effects of Smokeless Tobacco products. Brussels: European Commission; 2008. Retrieved from: https://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_013.pdf.

World Health Organization. Partial guidelines for implementation of articles 9 and 10 of the WHO framework convention on tobacco control. Geneva: World Health Organization; 2012.

The European Parliament and The Council of the European Union. Directive 2014/40/Eu of the European Parliament and of the Council of 3 April 2014 on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco and related products and repealing Directive 2001/37/EC; 2014. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ%3AJOL_2014_127_R_0001.

Blokhuis P. Voortgangsbrief Nationaal Preventieakkoord. Den Haag: Welzijn en Sport Ministerie van Volksgezondheid; 2020.

Campaign for Tobacco-Free Kids. Protect kids: fight flavored e-cigarettes. A year of progress, but youth e-cigarette use still at epidemic levels. Bold action needed to ban all flavored e-cigarettes. Campaign for Tobacco-Free Kids; 2020. https://www.tobaccofreekids.org/assets/content/press_office/2020/bloomberg-anniversary-report.pdf.

Carpenter CM, Connolly GN, Ayo-Yusuf OA, Wayne GF. Developing smokeless tobacco products for smokers: an examination of tobacco industry documents. Tob Control. 2009;18(1):54–9.

Kuiper NM, Gammon D, Loomis B, Falvey K, Wang TW, King BA, Rogers T. Trends in sales of flavored and menthol tobacco products in the United States during 2011–2015. Nicotine Tob Res. 2018;20(6):698–706.

Norwegian Institute of Public Health. Health risks from snus use [in Norwegian]. Oslo: Norwegian Institute of Public Health; 2019.

Lund KE, Vedøy TF. Relative risk perceptions between snus and cigarettes in a snus-prevalent society—an observational study over a 16 year period. Int J Environ Res Public Health. 2019;16(5):E879.

Pedersen W, von Soest T. Tobacco use among Norwegian adolescents: from cigarettes to snus. Addiction. 2014;109(7):1154–62.

Vedøy TF, Lund KE. Cigarette smoking in Norway [in Norwegian]. Oslo: Norwegian Institute of Public Health; 2018a.

Vedøy TF, Lund KE. Tobacco market composition and change [in Norwegian]. Oslo: Norwegian Institute of Public Health; 2018b.

Joossens L, Feliu A, Fernandez E. The Tobacco Control Scale 2019 in Europe. Brussels: Association of European Cancer Leagues, Catalan Institute of Oncology; 2020.

Vedøy TF, Lund M. Smoking cessation [in Norwegian]. Oslo: Norwegian Institute of Public Health; 2018c.

Scheffels J, Lund I. Cute as candy: a qualitative study of perceptions of snus branding and package design among youth in Norway. BMJ Open. 2017;7:e012837.

Adkison SE, Bansal-Travers M, Smith DM, O’Connor RJ, Hyland AJ. Impact of smokeless tobacco packaging on perceptions and beliefs among youth, young adults, and adults in the U.S: findings from an internet-based cross-sectional survey. Harm Reduct J. 2014;11:2–2.

Ambrose BK, Day HR, Rostron B, Conway KP, Borek N, Hyland A, Villanti AC. Flavored tobacco product use among US youth aged 12–17 years, 2013–2014. JAMA. 2015;314(17):1871–3.

Corey CG, Ambrose BK, Apelberg BJ, King BA. Flavored tobacco product use among middle and high school students-United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(38):1066–70.

Feirman SP, Lock D, Cohen JE, Holtgrave DR, Li T. Flavored tobacco products in the United States: a systematic review assessing use and attitudes. Nicotine Tob Res. 2016;18(5):739–49.

Johnston LD, O’Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the future national results on drug use: 1975–2013: overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan; 2014.

Villanti AC, Richardson A, Vallone DM, Rath JM. Flavored tobacco product use among U.S. young adults. Am J Prev Med. 2013;44(4):388–91.

Chaffee BW, Urata J, Couch ET, Gansky SA. Perceived flavored smokeless tobacco ease-of-use and youth susceptibility. Tob Regul Sci. 2017;3(3):367–73.

Kostygina G, Ling PM. Tobacco industry use of flavourings to promote smokeless tobacco products. Tob Control. 2016;25(Suppl 2):ii40–9.

Mejia AB, Ling PM. Tobacco industry consumer research on smokeless tobacco users and product development. Am J Public Health. 2010;100(1):78–87.

Harrell MB, Loukas A, Jackson CD, Marti CN, Perry CL. Flavored tobacco product use among youth and young adults: what if flavors didn’t exist? Tob Regul Sci. 2017;3(2):168–73.

Meier E, Vogel RI, O’Connor RJ, Severson HH, Shields PG, Hatsukami DK. Preference for flavored noncombustible nicotine products among smokers motivated to switch from cigarettes. Nicotine Tob Res. 2016;18(5):892–3.

Oliver AJ, Jensen JA, Vogel RI, Anderson AJ, Hatsukami DK. Flavored and nonflavored smokeless tobacco products: rate, pattern of use, and effects. Nicotine Tob Res. 2013;15(1):88–92.

Schneller LM, Lindgren BR, Shields PG, Hatsukami DK, O’Connor RJ. Strong preference for mint snus flavor among research participants. Addict Behav Rep. 2017;6:51–5.

Barbeau AM, Burda J, Siegel M. Perceived efficacy of e-cigarettes versus nicotine replacement therapy among successful e-cigarette users: a qualitative approach. Addict Sci Clin Pract. 2013;8:5.

Buckell J, Marti J, Sindelar JL. Should flavours be banned in cigarettes and e-cigarettes? Evidence on adult smokers and recent quitters from a discrete choice experiment. Tob Control. 2019;28:168–75.

Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos S, Spyrou A, Voudris V. Impact of flavour variability on electronic cigarette use experience: an internet survey. Int J Environ Res Public Health. 2013;10(12):7272–82.

Pacek LR, Rass O, Sweitzer MM, Oliver JA, McClernon FJ. Young adult dual combusted cigarette and e-cigarette users’ anticipated responses to hypothetical e-cigarette market restrictions. Subst Use Misuse. 2019;54(12):2033–42.

Pesko MF, Kenkel DS, Wang H, Hughes JM. The effect of potential electronic nicotine delivery system regulations on nicotine product selection. Addiction. 2016;111(4):734–44.

StataCorp. Stata statistical software release 15. College Station: StataCorp LLC; 2017.

Lund KE, Vedøy TF, Bauld L. Do never smokers make up an increasing share of snus users as cigarette smoking declines? Changes in smoking status among male snus users in Norway 2003–2015. Addiction. 2016;112(2):340–8.

Lund KE, Scheffels J, McNeill A. The association between use of snus and quit rates for smoking: results from seven Norwegian cross-sectional studies. Addiction. 2010;106(1):162–7.

Lund KE, McNeill A. Patterns of dual use of snus and cigarettes in a mature snus market. Nicotine Tob Res. 2013;15(3):678–84.

WHO Study Group on Tobacco Production Regulation. WHO Study Group on Tobacco Product Regulation. Report on the scientific basis of tobacco product regulation: third report of a WHO Study Group. WHO technical report series. Geneva: World Health organization; 2009.

Asthana S, Labani S, Kailash U, Sinha DN, Mehrotra R. Association of smokeless tobacco use and oral cancer: a systematic global review and meta-analysis. Nicotine Tob Res. 2019;21(9):1162–71.

Rostron BL, Chang JT, Anic GM, Tanwar M, Chang CM, Corey CG. Smokeless tobacco use and circulatory disease risk: a systematic review and meta-analysis. Open Heart. 2018;5:e000846.

U.S. Department of Health and Human Services. The health consequences of smoking—50 years of progress. A report of the surgeon general. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.

Lee PN. Epidemiological evidence relating snus to health—an updated review based on recent publications. Harm Reduct J. 2013;10:36.

Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino G, Hyland A, Sweanor D, Warner KE. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2035–42.

Nutt DJ, Phillips LD, Balfour D, Curran HV, Dockrell M, Foulds J, Fagerstrom K, Letlape K, Milton A, Polosa R, Ramsey J, Sweanor D. Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res. 2014;20(5):218–25.

Savitz DA, Meyer RE, Tanzer JM, Mirvish SS, Lewin F. Public health implications of smokeless tobacco use as a harm reduction strategy. Am J Public Health. 2006;96(11):1934–9.

U.S. Food & Drug Administration. FDA grants first-ever modified risk orders to eight smokeless tobacco products; 2019. Retrieved from: https://www.fda.gov/news-events/press-announcements/fda-grants-first-ever-modified-risk-orders-eight-smokeless-tobacco-products.

Kozlowski LT, Strasser AA, Giovino GA, Erickson PA, Terza JV. Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tob Control. 2001;10(3):201–3.

Gartner CE, Hall WD, Vos T, Bertram MY, Wallace AL, Lim SS. Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet. 2007;369(9578):2010–4.

The National Academies of Sciences. Engineering, and Medicine. Public health consequences of e-cigarettes. Washington, DC: The National Academies Press; 2018.

Vanyukov MM, Tarter RE, Kirillova GP, Kirisci L, Reynolds MD, Kreek MJ, Conway KP, Maher BS, Iacono WG, Bierut L, Neale MC, Clark DB, Ridenour TA. Common liability to addiction and “gateway hypothesis”: theoretical, empirical and evolutionary perspective. Drug Alcohol Depend. 2012;123(Suppl 1):S3-17.

Vedøy TF. From snus to abuse—prejudice or fact? J Nor Med Assoc. 2016;136(6):544–6.

Sooyong K, Selya AS. The relationship between electronic cigarette use and conventional cigarette smoking is largely attributable to shared risk factors. Nicotine Tob Res. 2019;22(7):1123–30.

Phillips CV. Gateway effects: why the cited evidence does not support their existence for low-risk tobacco products (and what evidence would). Int J Environ Res Public Health. 2015;12(5):5439–64.

Foxon F, Selya AS. Electronic cigarettes, nicotine use trends and use initiation ages among US adolescents from 1999 to 2018. Addiction. 2020.

Walker N, Parag V, Wong SF, Youdan B, Broughton B, Bullen C, Beaglehole R. Use of e-cigarettes and smoked tobacco in youth aged 14–15 years in New Zealand: findings from repeated cross-sectional studies (2014–19). Lancet Public Health. 2020;5(4):e204–12.

Thông tin
Thông tin xuất bản

Harm Reduction Journal

Thông tin tác giả